企业QQ
官方微信
转移机制的研究：转移起始细胞的分离和培养。
转移模型：转移细胞系和小鼠模型的发展。
药物发现：用于发现转移靶标的单细胞分选。
突变分析： 癌细胞的分离和培养，用于癌症基因组学DNA测序。
用于指导治疗的分子诊断：可以开发CTC和免疫细胞的整体基因表达谱，以指导单个患者的治疗。
心血管疾病的同伴诊断：基于循环内皮细胞（CEC）的血液检查可提高心血管疾病的风险。
怀孕期间胎儿细胞的基因检测： 在孕妇子宫或血液中的胎儿细胞，然后进行FACS，对孕妇的胎儿细胞进行基因检测。
针对seprase和DPP4的药物的开发：针对DPP4的单克隆抗体和针对seprase的肽抑制剂可抑制肿瘤的侵袭，转移和血管生成。
重要要推广的品牌Nanocs， chromotek， polysciences， echelon-inc ， Bio-Rad，伯乐 ， R&D Systems， Millipore，密理博 ， Jackson， NEB，New England Biolabs ，Sigma-Aldrich，西格玛奥德里奇， Athens Research & Technology， Illumina ， Tocris ， TwistDx， Enzymatics ，酶科技，Novus，Thermo，thermofisher，赛默飞，赛默飞世尔，gibco、invitrogen，英潍捷基，ambion、ebioscience、molecular probes、ABI，Applied Biosystems、Thermo Scientific，pierce。
苏州蚂蚁淘生物科技有限公司SuZhouebiomall BIOLOGicalTechnologyCo.,Ltd.成立于2017年，经过数年的努力已迅速成为集科研和生产为一体的专业化生物工程公司。特别是ELISA研发，代测，技术服务这一产品已使苏州蚂蚁淘成为中国知名公司。公司产品涵盖ELISA研发、细胞培养，各种生化试剂、各种酶类、分子生物学试剂盒、培养基、自产实验室耗材、小型仪器等。此外、苏州蚂蚁淘还代理了美国药典标准品，中检所标准品，sigma,ScienCell,ATCC,wak0,omega，Worthington、MBI、Bioworld、Calendon等国外各类知名公司的产品。苏州蚂蚁淘将进一步加强人才经营、产品经营，不断提升企业的核心竟争力，实现具有高科技产业体系、知识化创业团队的国际化的公司，服务于生命科学领域，迎接世界经济一体化所带来的机遇与挑战。
Vitatex is focused on advance personalized medicine with tests of invasive circulating tumor cells (iCTCs) that provide better information about the metastatic potential of a patient’s cancer to improve treatment and reduce health care costs. The company’s unique advantage stems from its patented approach that captures iCTCs directly linked to the metastatic process.Leveraging its functional Cell Adhesion Matrix (CAM) technology, Vitatex is developing proprietary diagnostic tests that can be run on blood samples, collected by standard current methods, to improve cancer treatment decisions and select effective therapies for recurrence and metastatic diseases.Improved Cancer Drug Selection: iCTCs captured by the Vitatex method are alive and can readily be cultured in the presence of panels of cancer drugs to optimize selection of treatment tailored to each patient. The ability to determine which cancer drug or drug cocktail is most likely to benefit a patient meets a major need which currently available methods have had only limited ability to address.Better Prognostic Information: CAM-captured iCTCs can be sorted and counted by automated flow cytometry to provide an early indication of metastasis in pre-operative patients, as well as early detection of recurrence in patients under therapeutic treatment. This greatly improved prognostic information can help the physician decide on aggressive chemo- therapy or other strategies more rapidly and confidently.Convenient and Effective Treatment Monitoring: Serial measurement of iCTCs in routinely collected patient blood samples during the course of treatment and beyond can monitor for effective response, relapse to allow a timely change of a failing therapy, or to reinitiate therapy following recurrence.The company’s technology also creates significant opportunities for research products and services that advance development of new cancer drugs and novel cancer markers, as well as support metastasis research. Companies developing new cancer drugs can access new models of metastasis and assay services that improve patient selection and monitoring in clinical trials. Vitatex has also developed proprietary metastatic cell lines and protein markers of invasiveness, including Seprase and DPP4, which strengthen the company’s testing methods and have potential cancer drug development applications.Vitatex has translated its patented CAM iCTC technology platform into a pipeline of promising innovative diagnostic tests that have entered clinical studies, and into enabling new research products and services. The company is pursuing these opportunities both through its own initiatives and through partnerships being developed with major diagnostic and research tool and service companies